4 Midcap Price to Sales Ratio 3-6 Stocks to Watch for Future Multibagger Potential: Lupin, SRF, Dabur and Astral

Price to sales ratio 3-6 stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Lupin, SRF, Dabur and Astral meet that test, with market caps from Rs 36,939 crore to Rs 91,955 crore and Lupin offering the highest return on equity at 23.76%. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and a price to sales ratio between 3 and 6, which is market capitalisation divided by FY26 revenue, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.

This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and a price to sales ratio between 3 and 6, which is market capitalisation divided by FY26 revenue, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening price to sales ratio 3-6 stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 28 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are Price to Sales Ratio 3-6 Stocks and Why Do They Attract Multibagger Interest?

Price to sales ratio 3-6 stocks are shares of mid sized companies whose market value is three to six times their yearly sales, a range that usually belongs to businesses with healthy margins and a record of steady growth. The four here cover pharmaceuticals, household products, specialty chemicals and pipes.

A mid-range price to sales ratio often reflects good margins and trusted management, and rising profit shows that the premium is being backed by real earnings. For price to sales ratio 3-6 stocks, both FY26 and the latest quarter showed growth. Investors researching price to sales ratio 3-6 stocks get a fuller picture by reading growth and valuation together. The table below lines up price to sales ratio 3-6 stocks on size, growth and valuation, using complete FY26 and latest quarter numbers. Past performance does not guarantee future returns, so use price to sales ratio 3-6 stocks as a starting point for your own research.

Price to Sales Ratio 3-6 Stocks at a Glance: Price, Market Cap, PE and ROE

Prices are closing prices as of 28 October 2026. Lupin combines the lowest PE of the group, 16.57, with the highest return on equity, 23.76%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Debt to Equity	52-Week Range (Rs)
Lupin	1,972.70	91,955	16.57	36.42	23.76%	0.29	1,900.00 to 2,529.50
SRF	2,350	74,551	34.48	36.15	13.07%	0.36	2,310.00 to 3,210.00
Dabur India	360	67,255	34.56	34.68	16.59%	0.11	357.80 to 534.00
Astral	1,360.60	36,939	64.16	36.61	13.18%	0.06	1,311.60 to 1,768.70

Lupin: Revenue Up 26.76% in FY26

Lupin is a global pharmaceutical company with a large presence in the United States, India and other markets across generics, branded drugs and respiratory products. It reported FY26 revenue of Rs 29,038.95 crore, up 26.76% year on year, and net profit of Rs 5,355.47 crore, up 61.98%. Revenue has compounded at 14.98% a year since FY22. Operating margin was 31.06% in FY26. The debt-to-equity ratio is 0.29.

In the June 2026 quarter, revenue rose 32.45% to Rs 8,407.21 crore and net profit grew 16.01% to Rs 1,416.98 crore. The share price has gained 111.00% over five years. Foreign investors raised their holding from 21.25% in June 2025 to 22.42% in June 2026. The stock trades at a PE of 16.57 against an industry PE of 36.42, below the sector average, with a return on equity of 23.76%.

SRF: Quarterly Profit Up 75.53%

SRF operates in specialty chemicals, packaging films and technical textiles, and its chemicals business is a key earnings driver. It reported FY26 revenue of Rs 15,893.57 crore, up 7.20% year on year, and net profit of Rs 1,835.18 crore, up 46.72%. Revenue has compounded at 6.08% a year since FY22. Operating margin was 21.74% in FY26. The debt-to-equity ratio is 0.36.

The stock trades at a PE of 34.48 against an industry PE of 36.15, below the sector average, with a return on equity of 13.07%. In the June 2026 quarter, revenue rose 31.69% to Rs 5,067.17 crore and net profit grew 75.53% to Rs 758.87 crore. Domestic institutions raised their holding from 18.85% in June 2025 to 22.44% in June 2026.

Dabur: Profit Compounding at 1.77% a Year

Dabur India is a leading Ayurveda and natural health care company with brands in hair care, oral care, juices and health supplements. It reported FY26 revenue of Rs 13,792.34 crore, up 5.18% year on year, and net profit of Rs 1,868.69 crore, up 7.37%. Revenue has compounded at 5.15% a year since FY22. Operating margin was 23.00% in FY26. The debt-to-equity ratio is 0.11, which keeps interest costs low.

In the June 2026 quarter, revenue rose 10.95% to Rs 3,936.95 crore and net profit grew 15.32% to Rs 586.16 crore. Domestic institutions raised their holding from 16.24% in June 2025 to 18.72% in June 2026. The stock trades at a PE of 34.56 against an industry PE of 34.68, below the sector average, with a return on equity of 16.59%. The dividend yield is 2.18%.

Astral: Debt-to-Equity of 0.06

Astral makes CPVC and PVC pipes, fittings, adhesives and water tanks for plumbing and drainage in homes and buildings. It reported FY26 revenue of Rs 6,615.90 crore, up 12.64% year on year, and net profit of Rs 534.70 crore, up 3.04%. Revenue has compounded at 10.55% a year since FY22. Operating margin was 16.54% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.

The stock trades at a PE of 64.16 against an industry PE of 36.61, with a return on equity of 13.18%. In the June 2026 quarter, revenue rose 16.09% to Rs 1,590.80 crore and net profit grew 51.77% to Rs 120.20 crore. Domestic institutions raised their holding from 14.90% in June 2025 to 21.31% in June 2026.

Price to Sales Ratio 3-6 Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these price to sales ratio 3-6 stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	Latest Quarter Revenue Growth	Operating Margin (Latest Quarter)
Lupin	29,038.95	5,355.47	26.76%	14.98%	32.45%	31.40%
SRF	15,893.57	1,835.18	7.20%	6.08%	31.69%	25.73%
Dabur	13,792.34	1,868.69	5.18%	5.15%	10.95%	24.27%
Astral	6,615.90	534.70	12.64%	10.55%	16.09%	15.46%

Check the Univest Screener for live data on these price to sales ratio 3-6 stocks

Institutional Holding in Lupin, SRF, Dabur and Astral

Institutional holding shows who is backing these price to sales ratio 3-6 stocks alongside the promoter. The table uses the latest reported quarter for each. Lupin has the deepest institutional backing, with FII and DII together holding 47.07% as of June 2026. Domestic institutions increased their holding over the past year in SRF (from 18.85% to 22.44%), Dabur (from 16.24% to 18.72%) and Astral (from 14.90% to 21.31%).

Stock	Promoter	FII	DII	Public	Quarter
Lupin	46.85%	22.42%	24.65%	6.08%	June 2026
SRF	50.26%	15.45%	22.44%	11.85%	June 2026
Dabur	66.24%	9.66%	18.72%	5.37%	June 2026
Astral	54.22%	13.89%	21.31%	10.58%	June 2026

Risks to Weigh in Price to Sales Ratio 3-6 Stocks

Being careful with price to sales ratio 3-6 stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Past growth may not repeat.
• Share prices can move sharply in either direction.
• Valuation: Astral trades at a PE of 64.16 against an industry PE of 36.61, so earnings need to keep growing to support the price.
• Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between Price to Sales Ratio 3-6 Stocks

Picking from price to sales ratio 3-6 stocks comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (34.68 to 36.61) and ask whether the growth rate justifies any gap.
3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Lupin, SRF, Dabur and Astral live prices.

Conclusion

Among price to sales ratio 3-6 stocks, Lupin stands out for the highest return on equity at 23.76%, SRF for the strongest latest-quarter profit growth at 75.53%, Dabur for 5.18% revenue growth in FY26 and Astral for a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.06. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing price to sales ratio 3-6 stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Price to Sales Ratio 3-6 Stocks to Watch

Which are the best price to sales ratio 3-6 stocks to watch for multibagger potential?

Ans. Lupin, SRF, Dabur and Astral are the 4 names this list highlights, with market caps of Rs 91,955 crore, Rs 74,551 crore, Rs 67,255 crore and Rs 36,939 crore respectively. Lupin is notable for the highest return on equity at 23.76%. SRF stands out for the strongest latest-quarter profit growth at 75.53%. Dabur offers 5.18% revenue growth in FY26. Astral brings a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.06. These are watchlist names for price to sales ratio 3-6 stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is Lupin a good stock for long-term investors?

Ans. Lupin has a return on equity of 23.76%, a PE of 16.57 against an industry PE of 36.42 and a market cap of Rs 91,955 crore. FY26 revenue rose 26.76%, and June 2026 quarter net profit grew 16.01%. Long-term returns in price to sales ratio 3-6 stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Astral become a multibagger from here?

Ans. Astral has a market cap of Rs 36,939 crore. A multibagger outcome in price to sales ratio 3-6 stocks requires earnings to keep growing faster than the market for several years. FY26 revenue rose 12.64%, and June 2026 quarter net profit grew 51.77%. At a PE of 64.16 against an industry PE of 36.61, valuation should be checked against that growth before investing.

What is the market cap of Lupin, SRF, Dabur and Astral?

Ans. As of 28 October 2026, Lupin has a market cap of Rs 91,955 crore, SRF has a market cap of Rs 74,551 crore, Dabur has a market cap of Rs 67,255 crore and Astral has a market cap of Rs 36,939 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on price to sales ratio 3-6 stocks.

What are the risks of investing in price to sales ratio 3-6 stocks?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Astral trades at a PE of 64.16 against an industry PE of 36.61, so earnings growth needs to hold up.

Why is Astral trading at a PE of 64.16?

Ans. Astral’s PE of 64.16 compares with an industry PE of 36.61. The market is paying a premium for latest-quarter profit growth of 51.77%, which also means the stock is more sensitive if growth slows. Investors in price to sales ratio 3-6 stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in Lupin, SRF, Dabur and Astral?

Ans. As of the latest reported quarter, FII and DII together hold 47.07% of Lupin (22.42% and 24.65%), 37.89% of SRF (15.45% and 22.44%), 28.38% of Dabur (9.66% and 18.72%) and 35.20% of Astral (13.89% and 21.31%). Rising institutional holding is a useful signal in price to sales ratio 3-6 stocks, though it should be read with earnings trends rather than on its own.